Interleukin Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026


#6702

Transparency Market Research

$ 5795

Interleukin (IL) are group of cytokines that are synthesized by lymphocytes, monocytes, macrophages, and other cells. They regulate cell growth, cell differentiation, and cell motility. Fifteen different types of interleukin are present in body. Interleukin inhibitors are immunosuppressive agents that inhibit the action of interleukins. Interleukin inhibitors are used in various conditions including asthma, ankylosing spondylitis, eczema, gout, arthritis (psoriatic and rheumatoid), psoriasis, and systematic sclerosis. Asthma is a chronic and long-term inflammatory disease of the lungs characterized by bronchospasm and airway obstruction. Ankylosing spondylitis is a type of arthritis that affects the spine. It affects about 0.1% to 0.5% of the adult population and can occur at any age. Eczema is a condition where patches of the skin become inflamed, itchy, red, cracked, and rough. It affects 31.6% of people in the U.S. Gout is a common and complex form of arthritis, characterized by severe joint pain. Psoriasis is non-contagious, chronic skin condition characterized by thickened and scaling skin. Systematic sclerosis is a connective tissue disease characterized by atrophy of the skin, vasomotor disturbance, and fibrosis.

Increase in the prevalence of chronic inflammatory diseases such as arthritis, psoriasis, and asthma is a major factor fueling the global interleukin inhibitors market. In addition to this, increase in FDA approvals for novel drugs and therapies for chronic inflammatory disease treatment is further boosting the market. For instance, in 2017, Dupixent monoclonal antibody that targets the interleukin 4 became the first biologic approved for atopic dermatitis. Moreover, the presence of a strong product pipeline and rise in awareness among people regarding chronic inflammatory diseases and their treatment in emerging economies are projected to propel the market in the near future. However, side effects and high cost associated with biological therapy are likely to hamper the global interleukin inhibitors market in next few years.

The global interleukin inhibitors market can be segmented based on disease condition, distribution channel, and region. Based on disease condition, the global interleukin inhibitors market can be categorized into asthma, ankylosing spondylitis, eczema, gout, arthritis (psoriatic and rheumatoid), psoriasis, systematic sclerosis, and others. In terms of distribution channel, the global market can be categorized into hospital pharmacies, online pharmacies, retail pharmacies, clinics, and research institutes.

In terms of region, the global interleukin inhibitors market can be divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to hold a prominent share of the global market, due to rise in the patient pool suffering from psoriasis, arthritis, asthma, and other chronic inflammatory diseases.  The presence of well-established drugs makers in North America is further expected to boost the market in the region. Additionally, according to the International Federation of Psoriasis Associations (IFPA), there are about 150,000 new cases of psoriasis every year in the U.S. According to a Centers for Disease Control and Prevention (CDC) report, in 2016, about 26,515 people lived with asthma in the U.S. Europe currently holds a strong position in the global interleukin inhibitors market. However, demand for interleukin inhibitors in the region is likely to decline due to intense competition among key players in the market in Europe. The market in Asia Pacific and Latin America is anticipated to expand at a rapid pace over the next few years due to rise in awareness regarding chronic inflammatory diseases, rapidly developing health care infrastructure, and increase in adoption of technology in these regions.

Key players operating in the global Interleukin inhibitors market are Regeneron Pharmaceuticals, Inc. Novartis AG, Valeant Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson., Genentech, Inc. (Roche), Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A., and AstraZeneca plc.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

  • Tailwinds and headwinds molding the market’s trajectory
  • Market segments based on products, technology, and applications
  • Prospects of each segment
  • Overall current and possible future size of the market
  • Growth pace of the market
  • Competitive landscape and key players’ strategies

The main aim of the report is to:

  • Enable key stakeholder’s in the market bet right on it
  • Understand the opportunities and pitfalls awaiting them
  • Assess the overall growth scope in the near term
  • Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.